Speciality: Pulmonary Medicine
Description:
A warm welcome to all the medical professionals in this interesting session on biologics target severe allergic asthma, improving lung function and reducing exacerbations.
Biologics are a breakthrough in treating severe allergic asthma, targeting specific immune pathways to reduce inflammation and improve symptoms. In individuals with severe asthma not well-controlled by standard medications, biologics offer a targeted approach, often by blocking key inflammatory molecules like interleukins or immunoglobulin E (IgE). These medications, typically monoclonal antibodies, help reduce asthma exacerbations, improve lung function, and enhance quality of life.
Biologics are especially effective in eosinophilic asthma subtypes, where elevated eosinophil levels indicate a more robust inflammatory response. Treatment selection is guided by patient-specific factors like biomarker profiles and treatment response. While biologics have revolutionized asthma management, their high cost and route of administration (usually via injection or infusion) are important considerations.
However, for individuals with severe allergic asthma unresponsive to traditional therapies, biologics offer hope for better symptom control and improved quality of life.
Therefore, get an overall knowledge on biologics target severe allergic asthma, improving lung function and reducing exacerbations.
See More Webinars @ Hidoc Webinars
1.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
2.
FDA approves Blenrep for relapsed or refractory multiple myeloma
3.
X-ray and radar technology combined to reduce cancer screening risks
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Researchers discuss HER2-low and HER2-zero in breast cancer
1.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
2.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
3.
The New Era of Oncology: Key Updates and Clinical Insights
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation